By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen will distribute a multiplex respiratory pathogen test manufactured by Celera, under an agreement announced today by the firms.

The molecular diagnostic test is the next-generation version of Qiagen's ResPlex II assay for detecting respiratory pathogens. The assay detects 19 different pathogens associated with respiratory infections and is designed for use on the LiquiChip 100 and 200 instrument platforms, which are based on Luminex's technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.